Search Results for “diagnostic” – Page 12 – media

Medtronic and Siemens Healthineers reach a major collaboration

On September 25, local time, at the 39th Annual Meeting of the North American Spine Society (NASS) held in Chicago, Medtronic announced that it has established a partnership with Siemens Healthineers to explore opportunities to further expand advanced preoperative and postoperative imaging technologies for spine care. Medtronic and Siemens Healthineers plan to bring the Siemens Healthineers Multitom Rax™ imaging system to market and integrate the platform into Medtronic’s spine surgery AiBLE™ ecosystem. The two companies also hope to collaborate on technology development, marketing and commercial activities to improve clinical outcomes. Multitom Rax™ can be used for musculoskeletal diseases, including spinal patients. Multitom Rax™ features standing, weight-bearing imaging, cone beam CT and supine x-ray capabilities, supporting Medtronic’s commitment to improving standards of care across the care continuum. Skip Kiil, president of Medtronic CranioSpinal Technology, said: “The collaboration with Siemens Healthineers advances our commitment to reduce variability and improve outcomes for spinal ...
- Source: drugdu
- 72
- September 28, 2024
Yuanruida ® The application for marketing authorization for the treatment of relapsed or refractory large B-cell lymphoma has been officially accepted

Juventas Biotech On September 26, 2024, the website of the Center for Drug Evaluation (CDE) of the National Medical Products Administration announced that Heyuan Biotechnology (Tianjin) Co., Ltd. (referred to as “Heyuan Biotechnology”) had launched its first CAR-T cell therapy product, Yuanruida ® The application for marketing authorization for the new indication of (Nakiolenza Injection) has been officially accepted, with acceptance number CXSS2400104, for the treatment of relapsed or refractory large B-cell lymphoma (r/r LBCL) after second-line or above systemic therapy. This is after the recurrence or refractory B-cell acute lymphoblastic leukemia (r/r B-ALL) in adults ® The second indication for submitting a new drug listing application domestically. This new drug listing application is based on a single arm, open label, multicenter critical clinical study (NCT04586478) jointly led by the Hematology Hospital of the Chinese Academy of Medical Sciences (Institute of Hematology, Chinese Academy of Medical Sciences) and Ruijin Hospital ...
- Source: drugdu
- 87
- September 27, 2024
【EXPERT Q&A】What is the difference between medical devices and non-medical devices?

Drugdu.com expert’s response: The differences between medical devices and non-medical devices are primarily manifested in the following six aspects: Ⅰ. Definition and Purpose Medical Devices: Refer to instruments, equipment, appliances, in vitro diagnostic reagents and calibrators, materials, and other similar or related articles, including the necessary computer software, that are directly or indirectly used on the human body. Their efficacy is primarily obtained through physical means rather than through pharmacology, immunology, or metabolism, or if these means are involved, they only play an auxiliary role. The primary purposes include diagnosis, prevention, monitoring, treatment, or alleviation of diseases, as well as diagnosis, monitoring, treatment, alleviation, or functional compensation of injuries. Non-Medical Devices: Generally refer to products that are not directly used on the human body or, even if in contact with the human body, do not have a medical purpose. They may be daily necessities, industrial products, consumer goods, such as ...
- Source: drugdu
- 77
- September 27, 2024
How to layout after recall and reorganization? Philips CEO responds

Recently, Roy Jakobs, CEO of Philips, gave an interview to foreign media and responded to questions such as how to reverse the company’s situation after a large-scale recall and the company’s restructuring plan. According to data, Philips was founded in the Netherlands in 1891 and mainly produces products in lighting, household appliances, and medical systems. The company has transformed from a Philips family business to a global multinational corporation managed by modern professional managers. In its 130 year history, it has evolved from a lighting business to a diversified enterprise that covers almost everything, and then continuously “slimmed down”. Eventually, it sold off its lighting business, leaving only medical care. It has successfully transformed from an electronics group into a global top medical technology giant, leading in the fields of imaging diagnosis, image-guided therapy, patient monitoring, health informatization, consumer health, and home care. In October 2022, Roy Jakobs became the ...
- Source: drugdu
- 92
- September 26, 2024
CMEH

Organiser：China Healthcare Industry Association, Chinese Medical Exchange Association Time：June 25 – 27, 2025 address：No. 1099 Guozhan Road or No. 111 Shiboguan Road, Pudong New Area, Shanghai, China Exhibition hall：Shanghai World Expo Exhibition & Convention Center Product range: Medical Imaging: CT, DR, Medical X-ray Systems, Ultrasound Diagnostic Instruments, MRI Equipment, Tumor Treatment Machines, Medical Film and Processing Systems, etc.; Remote & Mobile Intelligent Medical Monitoring: Sleep Monitors, Remote ECG, Blood Pressure, Blood Oxygen, Body Temperature Monitoring, Cloud Blood Pressure Monitors, Bluetooth Blood Pressure & Blood Glucose Monitors, Wearable Medical Devices, Health Kiosks, etc.; Diagnostic & Therapeutic Equipment: Endoscopy Systems, ENT Treatment Instruments, Dynamic Analysis Instruments, Cryogenic Freezing Equipment, Dialysis Treatment Equipment, Emergency Equipment, Surgical Instruments, Electrosurgical Units & Consumables, Laser Surgical Instruments, Ultrasound Surgery, etc.; Ward Nursing Equipment & Appliances: Beds, Trolleys, Tables, Cabinets, Racks, etc.; Disinfection Products: Medical Air Sterilizers, Vacuum Sterilizers, Ultrasonic Cleaning Systems, Disinfectants/Solutions, etc.; Auxiliary Products: ...
- Source: drugdu
- 197
- September 26, 2024
Cardinal Health Acquires ION for $1.115 Billion

Recently, Cardinal Health, the world’s ninth largest medical device company, announced that it has signed a final agreement to acquire Integrated Oncology Network (ION) for $1.115 billion (approximately RMB 7.861 billion) in cash to expand its oncology services business. INO is an independent community cancer center operator with over 50 clinics, more than 100 suppliers, and over 1000 healthcare workers in 10 states across the United States. It provides comprehensive care services for communities in areas such as medical oncology, radiation oncology, urology, and diagnostic testing. After this acquisition, all assets of ION will be integrated into the Navista Cancer Care division of Gardenor, and ION’s clinics will also receive Navista’s artificial intelligence analysis capabilities, as well as PPS Analytics platform support previously acquired by Gardenor through the acquisition of Specialty Networks. Navista is a subsidiary of Gardenor, a cancer diagnosis and treatment department jointly established with oncologists and clinic ...
- Source: drugdu
- 105
- September 25, 2024
When will it become the global TOP20? Mindray’s latest response

Recently, Mindray Medical disclosed the record of the investor relations event held on September 14, and answered several questions of concern to investors. Among them, “North American growth is lower than expected”, “future performance guidance targets”, mergers and acquisitions, AI medical layout and other issues have become the focus of this meeting. In this regard, Mindray Medical also answered from relevant perspectives. Among them, when mentioning future performance guidance, Mindray Medical said that based on the current situation, the company still has strong confidence that it can successfully achieve the goal of global medical device TOP20 in 2025 at the latest according to the established plan. Achieve global medical device TOP20 at the end of 2025 at the latest. According to the data, Mindray Medical mainly has three major production lines: life information and support, in vitro diagnosis and medical imaging. In recent years, it has also begun to focus ...
- Source: drugdu
- 70
- September 25, 2024
Domestic endoscopy giant acquires European counterparts

On September 18, Micro-Tech (NL) International B.V. announced that the company intends to use its own funds of no more than 36.72 million euros (equivalent to approximately 289 million yuan) to purchase 51% of the shares of Creo Medical S.L.U. (hereinafter referred to as “CME”) held by CreoMedical Group plc (hereinafter referred to as “Creo”) through its wholly-owned subsidiary Micro-Tech (NL) International B.V. After the completion of this transaction, CME will become a holding subsidiary of the company. The announcement shows that Creo is a medical device company headquartered in the UK and listed on the London Stock Exchange (stock code: CREO). Creo focuses on the development and commercialization of minimally invasive surgical equipment in the field of surgical endoscopy. Its main product is CROMA, an electrosurgical platform that can provide microwaves and bipolar radiofrequency for local cutting through a single accessory port, providing doctors with simplified and controllable surgical ...
- Source: drugdu
- 83
- September 24, 2024
Former President of Johnson & Johnson Orthopedics jumps to orthopedic giant!

Johnson & Johnson has had frequent executive changes in recent years, not only in the innovative pharmaceutical industry, but also in the medical technology department. At least nine executive changes have been reported since 2023. Recently, Enovis, a global orthopedic giant, announced the appointment of Tim Czartoski as president of its U.S. surgical and global products and supporting technologies business. Tim Czartoski previously worked in the DePuy Synthes orthopedic business unit of Johnson & Johnson Medical Technology. Tim Czartoski is a very experienced veteran in the medical field. He has more than 20 years of experience in the medical technology industry, especially in the orthopedic business. Tim Czartoski has held several key positions at Johnson & Johnson, leading the growth of Johnson & Johnson’s business. Looking back at Tim Czartoski’s career at Johnson & Johnson, he has held several positions in the DePuy Synthes orthopedic business unit of Johnson & ...
- Source: drugdu
- 78
- September 21, 2024
1.5 billion, the equipment giant is selling off this business

Recently, Merit Medical announced that it has agreed to acquire Cook Medical’s lead management business for $210 million (approximately RMB 1.5 billion). Merit expects to provide funding for the transaction through a combination of cash on hand and borrowing under its long-term credit line. The proposed transaction is expected to be completed in the fourth quarter of 2024, subject to obtaining or waiving (in accordance with the provisions of the asset purchase agreement) approval for certain closing conditions, including antitrust laws and other customary closing conditions. It is understood that Cook Medical’s lead management business has a 34 year operating history, providing a comprehensive end-to-end medical device and accessory product portfolio for patients who need to remove or replace pacemaker or implantable cardioverter defibrillator (ICD) leads for lead management procedures. 01. Breaking through industry difficulties Cook Medical’s lead management business provides medical equipment and accessories for potential customer management programs. ...
- Source: drugdu
- 90
- September 20, 2024

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.